Headline
The latest stories from AHA Today.
The full U.S. Court of Appeals for the District of Columbia Circuit denied AHA’s request to reconsider two decisions from this summer that upheld the Centers for Medicare & Medicaid Services’ cuts to payments for 340B drugs and for off-campus hospital outpatient clinic visits.
The AABB, America’s Blood Centers and the American Red Cross urged eligible individuals to donate blood, calling the nation’s blood supply “critically low.”
A new analysis by Global Health 50/50, an initiative to advance gender equality in global health, sheds light on sex disparities in COVID-19 deaths.
The Department of Health and Human Services announced the new option of saliva tests at federal community-based testing sites in areas experiencing COVID-19 surge.
Jim Skogsbergh, president and CEO of Advocate Aurora Health, will join AHA Board Chair Melinda Estes, M.D., Oct. 22 at 3:30 p.m. ET to discuss COVID-19’s impact on health trends and key strategies for reimagining and innovating care during and beyond the pandemic.
The Department of Health and Human Services announced a pair of innovation challenges aimed at improving maternal and infant health.
Access to potentially life-saving mammograms is more difficult for women who face social determinants of health such as low-income, lack of transportation or the inability to take time off from work.
The Centers for Medicare & Medicaid Services announced Georgia can move forward with a limited Medicaid expansion plan under which enrollees up to 100% of the federal poverty level must comply with, and report, work or other qualifying activities.
A recent article on hospital field finances ignores the diverse experiences of hospitals during the pandemic, particularly those under significant financial pressure, writes Aaron Wesolowski, AHA’s vice president of policy research, analytics and strategy.
The National Institutes of Health announced the start of an adaptive phase 3 clinical trial to evaluate the safety and efficacy of three immune modulator drugs in hospitalized adults with COVID-19.